

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 10/763,545  
Filed : January 23, 2004  
Page 2

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-108. (Canceled)

109. (Previously Presented) A composition which comprises a monoclonal antibody or a fragment of such antibody, wherein the monoclonal antibody or fragment of such antibody binds to the same epitope as antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) and a carrier.

110. (Currently Amended) The composition of claim 109, wherein the monoclonal antibody or the fragment of such antibody ~~consists of~~ comprises complementarity determining regions (CDRs) derived from the hybridoma cell line designated PA14 (ATCC Accession No. HB12610).

111. (Previously Presented) The composition of claim 110, wherein the monoclonal antibody is the monoclonal antibody designated PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) or a fragment of antibody PA14 which binds to an epitope of chemokine receptor 5 (CCR5) present on the surface of a cell expressing CCR5.

112. (Previously Presented) The composition of claim 109 or claim 110, wherein the monoclonal antibody or fragment of such antibody is humanized.

113. (Previously Presented) The composition of claim 112, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule.

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 10/763,545  
Filed : January 23, 2004  
Page 3

114. (Previously Presented) The composition of claim 113, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
115. (Previously Presented) The composition of claim 113, wherein the humanized antibody comprises a framework from a human IgG2 immunoglobulin molecule.
116. (Previously Presented) The composition of claim 113, wherein the humanized antibody comprises a framework from a human IgG4 immunoglobulin molecule.
117. (Previously Presented) The composition of claim 109 or claim 110, wherein the monoclonal antibody is a chimeric antibody.
118. (Currently Amended) The composition of claim 141, wherein the chimeric antibody comprises a constant region of a human IgG2 immunoglobulin molecule.
119. (Currently Amended) The composition of claim 141, wherein the chimeric antibody comprises a constant region of a human IgG4 immunoglobulin molecule.
120. (Previously Presented) The composition of claim 109 or claim 110, wherein the antibody fragment is a fragment of a humanized antibody.
121. (Currently Amended) The composition of claim 142, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.
122. (Currently Amended) The composition of claim 142, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.
123. (Previously Presented) The composition of claim 109, wherein the

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 10/763,545  
Filed : January 23, 2004  
Page 4

monoclonal antibody or fragment of such antibody is labeled with a detectable marker.

124. (Previously Presented) The composition of claim 123, wherein the detectable marker is a radioactive marker or a fluorescent marker.
125. (Previously Presented) The composition of claim 109, wherein the composition further comprises at least one additive selected from the group consisting of antimicrobials, antioxidants, chelating agents and inert gases.
126. (Previously Presented) The composition of any of claims 109, 110, or 111, wherein the monoclonal antibody is present in a therapeutically effective dose and the carrier is a pharmaceutically acceptable carrier.
127. (Previously Presented) A method of treating a subject infected with HIV-1 which comprises administering to the subject an effective dose of the composition of any of claims 109, 110, or 111 so as to treat the subject.
128. (Previously Presented) The method of claim 127, wherein the monoclonal antibody or fragment of such antibody is humanized.
129. (Previously Presented) The method of claim 128, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule.
130. (Previously Presented) The method of claim 129, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
131. (Previously Presented) The method of claim 130, wherein the humanized antibody comprises a framework from a human IgG2 immunoglobulin molecule.

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 10/763,545  
Filed : January 23, 2004  
Page 5

132. (Previously Presented) The method of claim 130, wherein the humanized antibody comprises a framework from a human IgG4 immunoglobulin molecule.
133. (Previously Presented) The method of claim 127, wherein the antibody fragment is a fragment of a humanized antibody.
134. (Currently Amended) The method of claim 143, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.
135. (Currently Amended) The composition of claim 143, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.
136. (Previously Presented) The method of claim 127, wherein the monoclonal antibody or fragment of such antibody is administered in a pharmaceutically acceptable carrier.
137. (Previously Presented) The method of claim 127, wherein the dose of the monoclonal antibody or fragment of such antibody is 0.1 to 100,000  $\mu\text{g/kg}$  body weight of the subject.
138. (Previously Presented) The method of claim 127, wherein the dose is administered by a route selected from the group consisting of oral, rectal, intra-vaginal, topic, nasal, ophthalmic and parenteral routes of administration.
139. (Previously Presented) The method of claim 138, wherein the parenteral route comprises subcutaneous, intramuscular, intravenous or intra-sternal administration.
140. (Previously Presented) The method of claim 127, wherein multiple doses are administered to the subject.
141. (New) The composition of claim 117, wherein the chimeric antibody

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 10/763,545  
Filed : January 23, 2004  
Page 6

comprises a constant region of a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

142. (New) The composition of claim 120, wherein the humanized antibody fragment comprises a fragment of a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
143. (New) The method of claim 133, wherein the humanized antibody fragment comprises a fragment of a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.